The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 5 µg/ml.
Use a concentration of 1 µg/ml. Predicted molecular weight: 18 kDa.
Use a concentration of 2.5 µg/ml.
Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K.
Expressed at highest levels in fetal and adult liver, followed by fetal heart, kidney, and lung, adult heart, and pancreas.
Involvement in disease
Defects in VKORC1 are a cause of combined deficiency of vitamin K-dependent clotting factors type 2 (VKCFD2) [MIM:607473]. VKCFD leads to a bleeding tendency that is usually reversed by oral administration of vitamin K. Defects in VKORC1 are a cause of coumarin resistance (CMRES) [MIM:122700]; also known as warfarin resistance. Warfarin and other coumarin-type anticoagulants are used to reduce blood viscosity in the treatment of thromboembolic disorders.